Pharmafile Logo

Considerations for Planning Effective and Appealing Advisory Boards: Importance of Participant Preferences

Explore our peer-reviewed article, “Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.” Dive into key findings on HCPs’ preferences for virtual and hybrid meetings, revealing their desire for frequent interactions and the impactful use of their insights. Discover why virtual options are favored for their convenience, inclusivity, and lower environmental impact.

Pharmaceutical advisory boards and other small-group meetings with health care providers (HCPs) are important for getting feedback on new clinical trial results, competitors’ products, or educational campaigns. However, they are typically expensive and require participants to travel long distances and take time away from their work and families. For in-person meetings, there are also issues with not everyone being able to contribute as much as they want, and the exclusion of people living in remote or underserved communities is common.

These days, pharmaceutical companies have a choice between hosting meetings in person, virtually, or using a hybrid approach. In making this choice, the cost and organizer’s preference are usually key considerations, but very few people ask the participants what they prefer.

To help answer this question and elucidate the preferred meeting format, frequency, and follow-up approach, we conducted a short feedback survey among HCPs participating in virtual advisory boards in 2022 and 2023. The results were recently published in Pharmaceutical Medicine.

Key findings included that:

  • The majority of health care providers prefer virtual or hybrid pharmaceutical meetings/advisory boards over in-person-only meetings.
  • Health care providers prefer to meet at least 2–4 times per year and want to receive continuous updates on how the pharmaceutical company is using their insights.
  • Key benefits of virtual versus in-person meetings include their superior convenience and flexibility, low environmental impact, and the ability to hear from more diverse participants.

Access the full article here, titled Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Digital technologies: Pharma’s answer to achieving net zero emissions?

As I wrote about earlier this year, it is clear that the climate crisis is no longer something for future generations to worry about, it’s already here and requires our urgent...

The Real-Time Health System: Accelerating Workflows with Data

Bree Bush, Vice President, Chief Data Officer at GE Healthcare, dives into simulation modeling and advanced analytical tools to optimize inpatient, procedural, and clinic capacity; the concept of “real-time healthcare”;...

The Future of eHealth: Contactless Health Monitoring

Laurence Pearce, CEO & Founder of Xim Ltd, creators of Lifelight®, discusses the need for personal health monitoring; traditional issues associated with population health screening; AI, machine learning, and computer...

Making Digital Trust and Privacy Accessible to Everyone

Mike Cook, CEO of IDENTOS, shares how his company is making digital trust and privacy accessible for patients, healthcare providers, payers, organizations, and connected devices. He also discusses “smart cities”...

Disrupting Cell Engineering with Non-Viral Modalities

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...

Congress eHuddle & Debrief Session: A Customer Story

How a Pharma team hosted daily MSL “eHuddles” during ASCO 2021 plus a post-congress debrief session using our asynchronous platform.

Healthcare Access and Payment Reform in the US

Chris Saxman, Senior Healthcare Executive, Head of Product Strategy at UCM Digital Health, shares his thoughts on the US healthcare system, including its flaws and how to fix it; the...

Advancing Drug Discovery with Structured and Intelligent Data

Michael Wilson and Craig Knox, co-founders of DrugBank, discuss how their comprehensive drug database can be used together with AI and machine learning for drug discovery and repurposing, clinical research,...

Digitalizing Muskuloskeletal Care to Improve Patient Outcomes and Reduce Cost

Lydia Zeller, CEO at Kiio, explores digital therapeutics, healthcare innovation, and Kiio’s innovative and personalized solutions for musculoskeletal (MSK) pain. She also shares her key leadership lessons and predictions for...

Accelerating Drug Development Timelines with Big Data Analytics

Barış Erdoğan, CEO of Clinerion, shares how medical data informatics and real-world EHR data can be used to improve the efficiency and effectiveness of patient searches, identification, and recruitment; clinical...